Arabic Arabic English English French French German German
dark

GSK and Vir Biotechnology Announce United States Government Agreement to Purchase Additional Supply of Sotrovimab, Authorized for the Early Treatment of COVID-19

GlaxoSmithKline plc (LSE/NYSE: GSK) and Vir Biotechnology, Inc. (Nasdaq: VIR) today announced that the US government will purchase an additional 600,000 doses of sotrovimab, an investigational monoclonal antibody for the early treatment of COVID-19, enabling further nationwide access to sotrovimab for patients. Read More

Total
0
Shares
Leave a Reply

Your email address will not be published. Required fields are marked *

Previous Post

Nearly 48,000 boosters given yesterday; 14 community cases; 34 people in hospital; two in ICU

Next Post

Ketamine and psychological therapy helped severe alcoholics abstain for longer in trial

Related Posts
Total
0
Share